Rehab Measures Database
  1. Rehabilitation Measures Database
  2. Structured Clinical Interview for DSM-5-Clinician Version

Structured Clinical Interview for DSM-5-Clinician Version

Last Updated

Purpose

To systematically diagnose the most commonly seen DSM-5 diagnoses in clinical settings; characterize a study population in terms of current psychiatric diagnoses; and improve interviewing skills of students in the mental health professions, including psychiatry, psychology, psychiatric social work, and psychiatric nursing, and general health practitioners. 

Link to Instrument

Link to instrument

Acronym SCID-5-CV

Area of Assessment

General Health & Development
Sensation & Pain
Mental Functions

Assessment Type

Patient Reported Outcomes

Administration Mode

Paper & Pencil

Cost

Not Free

Actual Cost

$144.00

Cost Description

Cost figure is for non-APA member users. The cost for APA members is $115.20 and for APA resident-fellow members it is $108.00. Link to buy SCID-5 CV at: https://www.appi.org/Products/Interviewing/SET-of-SCID-5-CV-and-SCID-5-CV-Users-Guide. For the NetSCID-5, there is a per-interview fee of $25 and an annual per-user fee of $12/year. Link to buy NetSCID-5 through TeleSage Inc. at: https://www.telesage.com/netscid-5.

CDE Status

Not a CDE as of 9/11/2024

Populations

Cancer
Chronic Pain
Neurologic Conditions
Pediatric and Congenital Conditions
Mental Health

Key Descriptions

  • A total of 347 items that can be broken down into areas of interest to pursue during the semi-structured interview.
  • There is no possible minimum or maximum – only whether or not the diagnostic threshold is met.
  • Brief description of item scoring:
    ○ Ratings of criterion items
    ■ - = absent/subthreshold (for a symptomatic criterion on a continuum)
    ■ NO = a dichotomous criterion statement is clearly false
    ■ + = threshold (for a symptomatic criterion on a continuum
    ■ YES = a dichotomous criterion statement is clearly true
    ● typically requires an elaborated response to determine
  • Assesses 64 different diagnoses across 10 modules:
    ○ Module A: Mood Episodes and Persistent Depressive Disorder
    ■ Major depressive episode (current and past)
    ■ Manic episode (current and past)
    ■ Hypomanic episode (current and past)
    ■ Persistent Depressive Disorder (formerly Dysthymic Disorder) (current only)
    ■ Bipolar Disorder Due to Another Medical Condition (AMC)
    ■ Substance/Medication-Induced Bipolar Disorder
    ■ Depressive Disorder Due to AMC
    ■ Substance/Medication-Induced Depressive Disorder

    ○ Module B: Psychotic and Associated Symptoms
    ■ Delusions
    ■ Hallucinations
    ■ Disorganized Speech and Behavior
    ■ Catatonic Behavior
    ■ Negative Symptoms

    ○ Module C: Differential Diagnosis of Psychotic Disorders
    ■ Schizophrenia
    ■ Schizophreniform Disorder
    ■ Schizoaffective Disorder
    ■ Delusional Disorder
    ■ Brief Psychotic Disorder
    ■ Psychotic Disorder Due to AMC
    ■ Substance/Medication-Induced Psychotic Disorder
    ■ Other Specified Psychotic Disorder

    ○ Module D: Differential Diagnosis of Mood Disorders
    ■ Bipolar I Disorder
    ■ Bipolar II Disorder
    ■ Other Specified Bipolar Disorder
    ■ Major Depressive Disorder
    ■ Other Specified Depressive Disorder

    ○ Module E: Substance Use Disorders (past 12 months only)
    ■ Alcohol Use Disorder
    ■ Cannabis Use Disorder
    ■ Inhalant Use Disorder
    ■ Other Hallucinogen Use Disorder
    ■ Opioid Use Disorder
    ■ Phencyclidine Use Disorder
    ■ Sedative/Hypnotic/Anxiolytic Use Disorder
    ■ Stimulant Use Disorder
    ■ Other or Unknown Substance Use Disorder

    ○ Module F: Anxiety Disorders
    ■ Panic Disorder
    ■ Agoraphobia (current only)
    ■ Social Anxiety Disorder (current only)
    ■ Generalized Anxiety Disorder (current only)
    ■ Anxiety Disorder Due to AMC
    ■ Substance/Medication-Induced Anxiety Disorder
    ■ Other Specified Anxiety Disorder

    ○ Module G: Obsessive-Compulsive and Related Disorders and PTSD
    ■ Obsessive-Compulsive Disorder (current only) OC and Related Disorder Due to AMC Substance/Medication-Induced Obsessive-Compulsive and Related Disorder Posttraumatic Stress Disorder

    ○ Module H: Attention-Deficit/Hyperactivity Disorder
    ■ Attention-Deficit/Hyperactivity Disorder (current only)

    ○ Module I: Screening Questions for Other Disorders
    ■ Specific Phobia
    ■ Separation Anxiety Disorder
    ■ Hoarding Disorder
    ■ Body Dysmorphic Disorder
    ■ Trichotillomania
    ■ Excoriation Disorder
    ■ Insomnia Disorder
    ■ Hypersomnolence Disorder
    ■ Anorexia Nervosa
    ■ Bulimia Nervosa
    ■ Binge-Eating Disorder
    ■ Avoidant/Restrictive Food Intake Disorder
    ■ Somatic Symptom Disorder
    ■ Illness Anxiety Disorder
    ■ Intermittent Explosive Disorder
    ■ Gambling Disorder

    ○ Module J: Adjustment Disorder
    ■ Current Adjustment Disorder (Past 6 months)
  • Other important information:
    ○ Do not assume a person’s functioning without the treatment currently being used. For example, do not assume what their symptom presentation would look like if they were to stop taking an antidepressant.
    ○ Sources possible to obtain information from include patient account during interview, referral notes, observations of family members and friends, etc.
    ○ Ensure criterion meets clinical significance when rating each question.
    ○ Determine distinction between Other Specified Disorder and Unspecified Disorder, if applicable.
    ○ Available in English, Chinese, Dutch, German, Greek, Hungarian, Italian, Korean, Norwegian, Portuguese, Romanian, and Turkish.
    ○ Refer to the User’s Guide for further details.
    ○ A number of sample role-play and homework cases are also included to help clinicians learn how to use the SCID-5-CV.
    ○ The SCID is considered the gold standard for diagnosing DSM mental health conditions; therefore, it is typically used to validate other measurements.

Number of Items

347

Equipment Required

  • A set of manuals, including the Structured Clinical Interview for DSM-5 Disorders (SCID-5-CV), Clinician Version and User's Guide to Structured Clinical Interview for DSM-5 Disorders (SCID-5), Clinician Version

Time to Administer

30 - 120 minutes

Time to administer depends on a variety of factors:
● Number of disorders being assessed
● Diagnostic complexity of the subject
● Subject’s ability or lack thereof to succinctly describe his/her history and symptoms
● Administrator’s level of familiarity and experience with DSM-5 diagnostic criteria and the SCID-5 instrument
● 30-45 minutes average completion time for electronic version

Required Training

Training Course

Required Training Description

A clinician or trained mental health professional who is familiar with the DSM-5 classification and diagnostic criteria. No minimum degree requirement, rather clinical experience is the most crucial requirement with sufficient experience performing unstructured diagnostic evaluation.

Ideally, training should be as follows:
1. Study Sections 5-8 in the User’s Guide (https://telesage.com/netscid-5)
2. Review the SCID-5-CV until comfortable with questions and administration.
3. Read the SCID-5-CV questions out loud.
4. Practice administration with someone.
5. Watch the didactic video training program SCID 101.
6. Practice the role-plays with a colleague.
7. Watch sample interviews on the SCID website.
8. Practice interviews with real patients alongside colleagues.
9. Consider receiving feedback with an on-site SCID-5-CV training workshop.
10. Record and submit an interview to the Biometrics Research Department to receive feedback.

Additional training generally required for administrators with less clinical experience. These additional trainings include reference interviews and ratings, didactic webinars, knowledge examinations, on-site SCID-5 training, and off-site SCID-5 training, each with their own associated cost.

Role plays and homework practice are available at the end of the User’s Guide for additional practice.

Optional NetSCID-5 training videos at: https://telesage.com/netscid-5

Age Ranges

Adult

18 - 64

years

Elderly Adult

65 +

years

Instrument Reviewers

Hannah Fry, Rehabilitation Psychology student under the direction of Timothy Tansey, PhD, Rehabilitation Psychology & Special Education Department, School of Education, University of Wisconsin-Madison

Kevin Fearn, MS, Shirley Ryan AbilityLab 

ICF Domain

Body Function
Activity

Measurement Domain

Emotion
Cognition
Sensory

Professional Association Recommendation

Developed and recommended by the American Psychiatric Association

Considerations

  • The Clinician Version (CV) of the SCID for DSM-5 (SCID-5-CV), released in 2014, consists of 10 modules that cover 39 of the most common diagnoses seen in clinical practice and allows screening for an additional 16 diagnoses. Although it is easy to select individual SCID modules for administration, more complex customization of items and diagnoses within modules can be difficult to implement.
  • This is the Clinician Version, there are other versions for purposes of research (SCID-5-RV), clinical trials (SCID-5-CT), personality disorder diagnosis (SCID-5-PD), and alternative model for personality disorder diagnosis found in the DSM-5 Section III, Emerging Measures and Models (SCID-5-AMPD).
  • Reliability of the SCID is dependent on circumstances and individual clinician skills (User guide, p.108).
  • Administering the SCID-5-CV to people who have moderate or severe intellectual ability or who are otherwise too cognitively impaired to answer the questions, or to subjects who are too medically or psychiatrically ill to participate in an interview is not possible. The SCID-5 can still be used as a tool for gathering and documenting diagnostic information obtained from other sources (e.g., informants, previous records) with the application of the DSM-5 diagnostic algorithms.
  • This version includes page numbers of corresponding DSM-5 diagnostic criteria if the administrator wishes to follow up on diagnosis for the screened disorders.
  • Most diagnoses in SCID-5-CV focus on current clinical status given that current, rather than past, is most relevant for treatment decisions. “Current” depends on disorder. “Specifiers for DSM-5 (including severity) are applicable in the SCID when the disorder is considered to be ‘current.’”
  • Screening for drug and alcohol use takes place in the beginning Overview section, and assessing lifetime/current suicidal ideation and behavior has been added to this section as well.
  • NetSCID-5 is available—the first web-based, fully computerized version of the SCID-5 instruments with data immediately stored on HIPPA-compliant geo-redundant databases developed by TeleSaga Inc. in consultation with the SCID-5 authors.
  • With slight modification to the wording of questions, the age range can be expanded to include adolescents. Plans to develop SCID-5 versions for Children and Adolescents are underway, including self and parent/guardian reporting features.
  • The SCID-5-CV is available in many languages:
    • Simplified Chinese
    • Dutch
    • German
    • Greek
    • Hungarian
    • Italian
    • Korean
    • Norwegian
    • Portuguese
    • Romanian
    • Turkish

Pediatric and Congenital Conditions

back to Populations

Normative Data

Adolescent Attention Deficit Hyperactivity Disorder (ADHD): (Somma, A., Carlotta, D., Boni, F., et al., 2019; n = 217; male = 100%; mean age = 17.63 (1.50) years; 73 (33.6%) previously experienced one or more school failures; 45 (20.7%) manifested a severe behavior problem at school; SCID-5-CV-Attention-Deficit/Hyperactivity Scale; Italian translation)

Descriptive Statistics for SCID-5-CV-Attention Deficit/Hyperactivity Disorder Scale (n = 217)

Measure

Mean

Std. Dev.

SCID-5-CV-ADHD Total Score (number of symptoms)

6.00

3.67

SCID-5-CV-ADHD Hyperactivity Score (number of symptoms)

2.64

2.22

SCID-5-CV-ADHD Inattentive Score (number of symptoms)

3.36

2.12

 

Test/Retest Reliability

Attention-deficit/hyperactivity disorder: (Osorio, et al., 2019; n = 139)

  • Acceptable test-retest reliability (κ = 0.83)

Interrater/Intrarater Reliability

Adult attention-deficit/hyperactivity disorder: (Elbir et al., 2018)

  • Excellent interrater reliability (κ = 1.00)

Attention-deficit/hyperactivity disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 1.00)

Criterion Validity (Predictive/Concurrent)

Concurrent validity:

Attention-deficit/hyperactivity disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.95)

Construct Validity

Convergent validity:

Adolescent Attention Deficit Hyperactivity Disorder (ADHD): (Somma et al., 2019)

  • Adequate convergent validity of SCID-5-CV-ADHD Total Score with the Adult ADHD Self-Report Scale-6 Item Version (ASRS-6) Total Score (r = 0.55) and the Wender Utah Rating Scale (WURS) Total Score (r = 0.54)
  • Adequate convergent validity of SCID-5-CV-ADHD Hyperactivity Score with the ASRS-6 Total Score (r = 0.43) and the WURS Total Score (r = 0.50)
  • Adequate convergent validity of SCID-5-CV-ADHD Total Score with the ASRS-6 Total Score (r = 0.49) and the WURS Total Score (r = 0.43)
  • Adequate convergent validity of the SCID-5-CV-ADHD Total Score and the Personality Diagnostic Questionnaire-4+ (PDQ-4+) Conduct Disorder Scale Score (r = 0.37)
  • Adequate convergent validity of the SCID-5-CV-ADHD Hyperactivity Score and the PDQ-4+ Conduct Disorder Scale Score (r = 0.40)
  • Poor convergent validity of the SCID-5-CV-ADHD Inattentive Score and the PDQ-4+ Conduct Disorder Scale Score (r = 0.22) 

 

Discriminant validity:

Adolescent Attention Deficit Hyperactivity Disorder (ADHD): (Somma et al., 2019)

  • Participants who met DSM-5 criteria for adult ADHD based on the SCID-5-CV ADHD module received significantly lower behavior (7.50 vs. 8.14, t(215) = -2.28, p < 0.05, d = -0.31) and school (6.4 vs. 6.8, t(215) = -2.03, p < 0.05, d = -0.28) grades than did participants who did not meet DSM-5 criteria for ADHD.
  • Previous school failures were not significantly associated with adult ADHD (t(215) = 0.74, p > 0.40, d = 0.10)

Chronic Pain

back to Populations

Construct Validity

Discriminant validity:

Chronic Migraine (CM): (Bottiroli et al., 2021; n = 75; age ≥ 18 and ≤ 65 years; mean age = 49.5 years; age range = 22-65; female = 71%; fulfillment of ICHD-3 criteria for CM or CM + acute medication overuse for at least 12 months prior to treatment with Erenumab; previous failure of at least three different pharmacological classes of preventative therapies; Italian translation)

Significant discriminant validity between treatment groups based on SCID-5-CV

Condition

Respondersa n (%)

Non-Respondersa n (%)

p

Personality disorders

21 (40%)

18 (82%)

0.001

   Cluster C

19 (37%)

17 (77%)

0.001

Obsessive-compulsive

19 (36%)

15 (68%)

0.01

Anxiety disorders

32 (60%)

20 (90%)

0.007

aResponders to treatment = number of monthly headache days reduced by at least 50% compared to baseline; non-responders to treatment = reduction in migraine frequency was < 50%)

Cancer

back to Populations

Normative Data

Cancer-related stressors: (Springer, et al., 2023; n = 291; mean age = 54.5 (12.5); male = 174 (60%); German translation of SCID-5-CV)

Frequency and type of cancer-related stressors and (medical) traumatic events among 285 hematological cancer survivors assessed with SCID-5-CVa

Type of Stressor

n (valid %)

Cancer-related stressors

 

   At least one cancer-related stressor

168 (59)

      More than one cancer-related stressor

34 (12)

      Distribution among all reported cancer-       related stressors

213 (100)

         Disclosure of cancer diagnosis

58 (27)

         Physical side effects

21 (10)

         Social Stressors

8 (9)

         Other/unspecific

20 (9)

         Treatment complications

18 (8)

         Witnessing distressing events among other patients

16 (8)

         Spatial isolationb

14 (7)

         Patient-doctor interaction

15 (7)

         Specific oncological treatment procedures

12 (6)

         Psychological side effects

13 (6)

         Aspiration of bone marrow

10 (5)

         Receiving the diagnosis of relapse

4 (2)

         Detecting of symptoms

3 (1)

Cancer-related stressors meeting trauma criteria according to DSM-5

 

   Patients reporting any kind of cancer-related traumatic event

18 (8)

      Distribution among all cancer-related traumatic events

18 (100)

         Complications such as anaphylactic shock, sepsis, or pneumothorax

8 (10)

         Witnessing distressing events including anaphylactic shock or death

7 (9)

         Detecting symptoms

3 (4)

Events according to official trauma list

 

   At least one traumatic event

175 (70)

      More than one traumatic event

65 (26)

      Distribution among all reported traumatic events

271 (100)

         Witnessing death or sever injury of another person

110 (41)

         Experiencing a life-threatening situation

56 (21)

         Experiencing physical or sexual attack

53 (20)

         Witnessing physical or sexual attack

39 (14)

         Learning that traumatic event occurred to family member/friend

13 (5)

aSCID-5-CV = Structured Clinical Interview for DSM-5 Disorders – Clinical Version.

bPotential stressor in undergoing autologous/allogenic stem cell transplantation.

Neurologic Conditions

back to Populations

Construct Validity

Discriminant validity:

Chiari Malformation (CM): (Yilmaz, et al. (2022); n = 62 (29 asymptomatic adults age > 18 with type I CM who had not undergone decompression surgery and a control group of 33 volunteers without type I CM based on neurosurgery evaluations, but comparable to study group in terms of age, sex, and socioeconomic characteristics, with no neurological disorders, mental retardation, or previous presentation for psychiatric conditions); mean age of type I CM group = 37.59 (9.85), female = 83%; mean age of control group = 34.52 (7.37), female = 76%)

  • Significant difference between Chiari and control groups in terms of psychiatric comorbidities according to SCID-5-CV (p = 0.018)
    • Psychiatric disorders were detected in 11 participants (38%) in the Chiari group and 4 (12%) in the control group

Mental Health

back to Populations

Test/Retest Reliability

Depressive Disorders:

Persistent depressive disorder: (Osorio, et al., 2019; n = 180 (124 psychiatric patients followed-up at a general university hospital, 29 psychiatric inpatients, 7 psychiatric consultation liaison inpatients from the same university hospital, and 20 subjects with no history of psychiatric and/or psychological treatment); mean age = 38.3 (14.3); age range = 18-64; female = 54.4%; Brazilian sample)

  • Poor test-retest reliability (κ = 0.46)

Current major depressive disorder: (Osorio, et al., 2019)

  • Poor test-retest reliability (κ = 0.65)

Past major depressive disorder: (Osorio, et al., 2019)

  • Poor test-retest reliability (κ = 0.69)

Recurrent major depressive disorder: (Osorio, et al., 2019)

  • Excellent test-retest reliability (κ = 0.93)

Any major depressive disorder: (Osorio, et al., 2019)

  • Acceptable test-retest reliability (κ = 0.79)

 

Trauma- and Stressor-Related Disorders:

Posttraumatic stress disorder (current/past): (Osorio, et al., et al., 2019; n = 139)

  • Acceptable test-retest reliability (κ = 0.84)

 

Bipolar and Related Disorders:

Bipolar I disorder: (Osorio, et al., 2019; n = 139)

  • Excellent test-retest reliability (κ = 0.96)

Bipolar II disorder: (Osorio, et al., 2019; n = 139)

  • Excellent test-retest reliability (κ = 1.00)

Any bipolar disorder: (Osorio, et al., 2019; n = 139)

  • Excellent test-retest reliability (κ = 0.98)

 

Anxiety Disorders:

Generalized anxiety disorder: (Osorio, et al., 2019; n = 139)

  • Poor test-retest reliability (κ = 0.65)

Social anxiety disorder: (Osorio, et al., 2019; n = 139)

  • Poor test-retest reliability (κ = 0.68)

Panic disorder: (Osorio, et al., 2019; n = 139)

  • Poor test-retest reliability (κ = 0.52)

Agoraphobia: (Osorio, et al., 2019; n = 139)

  • Poor test-retest reliability (κ = 0.28)

Any anxiety disorder: (Osorio, et al., 2019; n = 139)

  • Acceptable test-retest reliability (κ = 0.71)

 

Substance Use Disorders:

Alcohol use disorder: (Osorio, et al., 2019; n = 139)

  • Poor test-retest reliability (κ = 0.55)

Non-alcohol substance use disorder: (Osorio, et al., 2019; n = 139)

  • Excellent test-retest reliability (κ = 0.92)

Any substance disorder: (Osorio, et al., 2019; n = 139)

  • Acceptable test-retest reliability (κ = 0.72)

 

Schizophrenia Spectrum and Other Psychotic Disorders:

Schizophrenia disorder: (Osorio, et al., 2019; n = 139)

  • Excellent test-retest reliability (κ = 0.92)

Any psychotic disorder: (Osorio, et al., 2019; n = 139)

  • Excellent test-retest reliability (κ = 0.96)

 

Obsessive-Compulsive and Related Disorders:

Obsessive-compulsive disorder: (Osorio, et al., 2019; n = 139)

  • Excellent test-retest reliability (κ = 0.89)

 

Mixed Diagnoses:

Mixed Diagnoses: (Shabani et al., 2020; n = 245; mean age = 35.91 (11.64); age range = 17-68; female = 57.1%; diagnoses include schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, depressive disorders, substance-related and addictive disorders, anxiety disorders, and obsessive-compulsive disorder)

  • Acceptable test-retest reliability for obsessive-compulsive disorder diagnosis: (phi coefficient = 0.774, p < 0.001)

Interrater/Intrarater Reliability

Depressive Disorders:

Major depressive disorder: (Elbir et al., 2018; n = 185; mean age = 37.2 (13.5); age ≥ 18; female = 55.7%; Turkish sample)

  • Excellent interrater reliability (κ = 0.89)

Dysthymic disorder: (Elbir et al., 2018)

  • Excellent interrater reliability (κ = 0.82)

Persistent depressive disorder: (Osorio, et al., 2019)

  • Adequate interrater reliability (κ = 0.70)

Current major depressive disorder: (Osorio, et al., et al., 2019)

  • Excellent interrater reliability (κ = 0.82)

Past major depressive disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.87)

Recurrent major depressive disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 1.00)

Any major depressive disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.98)

 

Trauma- and Stressor-Related Disorders:

Post-traumatic stress disorder: (Elbir et al., 2018)

  • Excellent interrater reliability (κ = 0.89)

Adjustment disorder: (Elbir et al., 2018)

  • Excellent interrater reliability (κ = 0.78)

Post-traumatic stress disorder (current/past): (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.97)

 

Bipolar and Related Disorders:

Bipolar disorder: (Elbir et al., 2018)

  • Excellent interrater reliability (κ = 0.96)

Bipolar I disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 1.00)

Bipolar II disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.94)

Any bipolar disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 1.00)

 

Anxiety Disorders:

Generalized anxiety disorder: (Elbir et al., 2018)

  • Excellent interrater reliability (κ = 0.89)

Social phobia: (Elbir et al., 2018)

  • Excellent interrater reliability (κ = 0.95)

Specific phobia: (Elbir et al., 2018)

  • Excellent interrater reliability (κ = 0.82)

Agoraphobia: (Elbir et al., 2018)

  • Excellent interrater reliability (κ = 0.85)

Panic disorder: (Elbir et al., 2018)

  • Excellent interrater reliability (κ = 0.84)

Generalized anxiety disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.92)

Social anxiety disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.97)

Panic disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.97)

Agoraphobia: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.85)

Any anxiety disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.97)

 

Substance Use Disorders:

Alcohol use disorder: (Elbir et al., 2018)

  • Excellent interrater reliability (κ = 0.96)

Alcohol use disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.91)

Non-alcohol substance use disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.97)

Any substance disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.98)

 

Schizophrenia Spectrum and Other Psychotic Disorders:

Schizophrenia: (Elbir et al., 2018)

  • Excellent interrater reliability (κ = 0.93)

Schizophrenia disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.97)

Schizoaffective disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 1.00)

Delusional disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.79)

Any psychotic disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 1.00)

 

Obsessive-Compulsive and Related Disorders:

Obsessive-compulsive disorder: (Elbir et al., 2018; n = 185; Mean Age = 37.2 (13.5); Turkish sample)

  • Excellent interrater reliability (κ = 0.87)

Obsessive-compulsive disorder: (Osorio, et al., 2019)

  • Excellent interrater reliability (κ = 0.95)

 

Somatic Symptom and Related Disorders:

Somatic symptom disorder: (Elbir et al., 2018)

  • Adequate interrater reliability (κ = 0.65)

 

Mixed Diagnoses:

Mixed Diagnoses: (Shabani et al., 2020; two examiners completing the interviews separately)

  • Excellent interrater reliability for all diagnoses: (phi coefficient >= 0.896, p < 0.001)

Criterion Validity (Predictive/Concurrent)

Concurrent validity:

 

Depressive Disorders:

Persistent depressive disorder: (Osorio, et al., 2019)

  • Adequate concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.52)

Current major depressive disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.87)

Past major depressive disorder: (Osorio, et al., 2019)

  • Adequate concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.66)

Recurrent major depressive disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.76)

Any major depressive disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.76)

 

Trauma- and Stressor-Related Disorders:

Post-traumatic stress disorder (current/past): (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.80)

 

Bipolar and Related Disorders:

Bipolar I disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.88)

Bipolar II disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.94)

Any bipolar disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.93)

 

Anxiety Disorders:

Generalized anxiety disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.61)

Social anxiety disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.71)

Panic disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.73)

Agoraphobia: (Osorio, et al., 2019)

  • Adequate concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.35)

Any anxiety disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.73)

 

Substance Use Disorders:

Alcohol use disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.84)

Non-alcohol substance disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.94)

Any substance disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.92)

 

Schizophrenia Spectrum and Other Psychotic Disorders:

Schizophrenia disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.83)

Any psychotic disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.93)

 

Obsessive-Compulsive and Related Disorders:

Obsessive-compulsive disorder: (Osorio, et al., 2019)

  • Excellent concurrent validity of SCID-5-CV with clinical diagnosis (κ = 0.82)

 

Mixed Diagnoses:

Mixed Diagnoses: (Shabani et al., 2020; n = 245; mean age = 35.91 (11.64); age range = 17-68; female = 57.1%)

SCID-5-CV and Psychiatrists’ Agreement (based on DSM-5 diagnostic criteria)

Diagnosis

Freq.1

Kappa

Sensitivity

Specificity

Schizophrenia & other psychotic disorders

46

0.9

0.89

0.98

Bipolar & related disorders

22

0.8

0.82

0.96

Depressive disorders

116

0.69

0.84

0.84

Substance-related & addictive disorders

25

0.76

0.88

0.96

Anxiety disorders

19

0.34

0.94

0.78

Obsessive-compulsive disorder

34

0.76

0.82

0.96

1By psychiatrists’ diagnosis (Gold standard)


 

Bibliography

Abdelghani, M., Fouad, A. A., Mamdouh, A., & Raya, Y. M. (2020). Association between cognitive impairment and substance use disorder attributed to pregabalin in Egypt: A case-control study. Addictive Disorders and Their Treatment, 19(4), 201-208. DOI: 10.1097/ADT.0000000000000223. 

American Psychiatric Association. (2020). The Structured Clinical Interview for DSM-5®. Retrieved November 16, 2020, from https://www.appi.org/scid5/structured-clinical-interview-for-dsm-5-scid-5.

Bottiroli, S., De Icco, R., Vaghi, G., Pazzi, S., et al. (2021). Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study. The Journal of Headache and Pain, 22:114. https://doi.org/10.1186/s10194-021-01333-4

Elbir, M., Topbas, O. A., Bayad, S., Kocabas, T., Topak, O. Z., Cetin, S., . . . Aydemir, O. (2019). Adaptation and reliability of the Structured Clinical Interview for DSM-5-Disorders - Clinician Version (SCID-5/CV) to the Turkish language. Turkish Journal of Psychiatry, 30(1), 51-56. doi:10.5080/u23431. Find it on PubMed

First MB, Williams JBW, Karg RS, Spitzer RL: Structured Clinical Interview for DSM-5 Disorders, Clinician Version (SCID-5-CV). Arlington, VA, American Psychiatric Association, 2016

First MB, Williams JBW, Karg RS, Spitzer RL: User’s Guide for the Structured Clinical Interview for DSM-5 Disorders, Clinician Version (SCID-5-CV). Arlington, VA, American Psychiatric Association, 2016, Copyright © 2016 American Psychiatric Association

Osório, F. L., Loureiro, S. R., Hallak, J. E., Machado‐De‐Sousa, J. P., Ushirohira, J. M., Baes, C. V., . . . Crippa, J. A. (2019). Clinical validity and intrarater and test–retest reliability of the Structured Clinical Interview for DSM‐5 – Clinician Version (SCID‐5‐CV). Psychiatry and Clinical Neurosciences, 73(12), 754-760. doi:10.1111/pcn.12931. Find it on PubMed

Shabani, A., Masoumian, S., Zamirinejad, S., Hejri, M., Pirmorad, T., & Yaghmaeezadeh, H. (2020). Psychometric properties of Structured Clinical Interview for DSM-5 Disorders-Clinician Version (SCID-5-CV). Brain and Behavior, 11, e01894. https://doi.org/10.1002/brb3.1894

Somma, A., Carlotta, D., Boni, F., Arlotta, E., Masci, E., Busso, S. Cerioli, C., Manini, R., Borroni, S., & Fossati, A. (2019). Reliability and validity of the Structured Clinical Interview for DSM-5-Clinician Version (SCID-5-CV) Attention Deficit/Hyperactivity Disorder Criteria: preliminary evidence from a sample of 217 Italian adolescents. Journal of Psychopathology, 25, 3-9.

Springer, F., Friedrich, M., Kuba, K., Ernst, J., et al. (2023). New progress in an old debate? Applying the DSM-5 criteria to assess traumatic events and stressor-related disorders in cancer survivors. Psycho-Oncology, 32:1616-1624.  https://doi.org/10.1002/pon.6213   

Yilmaz, Y., Karademir, M., Caygin, T., Yagcioglu, O. K., Ozum, U., & Kugu, N. (December 2022). Executive Functions, Intellectual Capacity, and Psychiatric Disorders in Adults with Type 1 Chiari Malformation. World Neurosurgery, 168:e607-e612

 

rehabilitation measures

More Instruments Like This

We have reviewed more than 500 instruments for use with a number of diagnoses including stroke, spinal cord injury and traumatic brain injury among several others.

updated Jun 5, 2025

Allen Cognitive Level Scre...

read more

updated Jan 14, 2025

Work and Social Adjustment...

read more

updated Oct 31, 2024

Sollerman Hand Function Te...

read more